Amidst large investment from parent company, Samsung Biologics seeks to ramp up biotech funding

Last month, it was reported that South Korea’s Samsung Group raised spending by more than 30% to KRW 450 trillion, or around $360 billion, to invest in several lines of business including electronics and biotech, among others. Samsung Biologics CEO John Rim spoke to Endpoints at #BIO22 to discuss how this investment will affect the biotech arms of one of South Korea’s largest conglomerates.